ArticleAmerican journal of translational research2023
Durable responses to tislelizumab plus fruquintinib and radiotherapy in refractory microsatellite stable metastatic colorectal cancer: a case report.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Bicentric lesion of colon cancer with postoperative fever: A case report.Oncology letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has changed the landscape of contemporary cancer treatment. Different from microsatellite instability-high colorectal cancer (CRC), the microsatellite-stable (MSS) CRC shows little response to immunomonotherapy. Reasonable drug combinations may be a valuable exploration to solve this the dilemma. Here, we report a young patient with refractory metastatic rectal adenocarcinoma at stage IVb who achieved a durable partial response after receiving tislelizumab plus fruquintinib and well-timed local radiotherapy. To date, the patient has a progression-free survival of more than 12 months with obviously declined serum tumor markers, increased peripheral blood effector T cells, alleviated scrotal edema and improved quality of life. This case suggests that an immune checkpoint inhibitor combined with an anti-VEGFR-tyrosine kinase inhibitor and local radiation intervention might be an effective strategy for heavily pretreated metastatic CRC patients with MSS phenotype.
Indexed as
Identifiers
37193166PMC10182488W4376872368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.